| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $0 | 0 | 0 |
Sells | $3,163,455 | 38 | 100 |
| Lezack Adam | director | 0 | $0 | 2 | $79,323 | $-79,323 |
| Palasis Maria | director | 0 | $0 | 2 | $79,386 | $-79,386 |
| Russell Steven Jon | Chief Medical Officer | 0 | $0 | 4 | $80,487 | $-80,487 |
| Saint Sean | President & CEO | 0 | $0 | 4 | $262,882 | $-262,882 |
| Mensinger Mike | Chief Product Officer | 0 | $0 | 6 | $381,998 | $-381,998 |
| Hopman Mark | Chief Commercial Officer | 0 | $0 | 9 | $773,436 | $-773,436 |
| Feider Stephen | Chief Financial Officer | 0 | $0 | 11 | $1.51M | $-1.51M |
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
Over the last 12 months, insiders at Beta Bionics, Inc. have bought $0 and sold $3.16M worth of Beta Bionics, Inc. stock.
On average, over the past 5 years, insiders at Beta Bionics, Inc. have bought $0 and sold $3.16M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-03-04 | Sale | Hopman Mark | Chief Commercial Officer | 353 0.0008% | $11.57 | $4,084 | -5.14% | |
| 2026-03-02 | Sale | Saint Sean | President & CEO | 3,384 0.0075% | $12.36 | $41,832 | -13.74% | |
| 2026-03-02 | Sale | Mensinger Mike | Chief Product Officer | 1,064 0.0023% | $12.36 | $13,153 | -13.74% | |
| 2026-03-02 | Sale | Russell Steven Jon | Chief Medical Officer | 1,026 0.0023% | $12.36 | $12,683 | -13.74% | |
| 2026-03-02 | Sale | Feider Stephen | Chief Financial Officer | 1,428 0.0031% | $12.36 | $17,652 | -13.74% | |
| 2026-03-02 | Sale | Hopman Mark | Chief Commercial Officer | 834 0.0018% | $12.36 | $10,310 | -13.74% | |
| 2026-01-06 | Sale | Mensinger Mike | Chief Product Officer | 2,200 0.0048% | $30.10 | $66,221 | -58.74% | |
| 2026-01-02 | Sale | Mensinger Mike | Chief Product Officer | 7,800 – | $29.61 | $230,950 | -55.44% | |
| 2026-01-02 | Sale | Feider Stephen | Chief Financial Officer | 20,000 – | $29.53 | $590,680 | -55.44% | |
| 2025-12-04 | Sale | Hopman Mark | Chief Commercial Officer | 2,061 0.0046% | $30.66 | $63,192 | -54.13% | |
| 2025-12-02 | Sale | Russell Steven Jon | Chief Medical Officer | 1,025 0.0022% | $29.34 | $30,069 | -51.37% | |
| 2025-12-02 | Sale | Hopman Mark | Chief Commercial Officer | 856 0.0018% | $29.34 | $25,112 | -51.37% | |
| 2025-12-02 | Sale | Saint Sean | President & CEO | 3,278 0.007% | $29.34 | $96,163 | -51.37% | |
| 2025-12-02 | Sale | Mensinger Mike | Chief Product Officer | 1,063 0.0023% | $29.34 | $31,184 | -51.37% | |
| 2025-12-02 | Sale | Feider Stephen | Chief Financial Officer | 1,427 0.003% | $29.34 | $41,862 | -51.37% | |
| 2025-12-01 | Sale | Palasis Maria | director | 1,406 0.003% | $29.55 | $41,552 | -53.10% | |
| 2025-12-01 | Sale | Lezack Adam | director | 1,406 0.003% | $29.55 | $41,543 | -53.10% | |
| 2025-10-31 | Sale | Palasis Maria | director | 1,406 0.0027% | $26.91 | $37,834 | -44.18% | |
| 2025-10-31 | Sale | Lezack Adam | director | 1,406 0.0027% | $26.87 | $37,780 | -44.18% | |
| 2025-10-03 | Sale | Feider Stephen | Chief Financial Officer | 4,982 0.0078% | $21.69 | $108,076 | -13.48% |
| Increased Positions | 108 | +97.3% | 9M | +17.74% |
| Decreased Positions | 46 | -41.44% | 9M | -19.56% |
| New Positions | 47 | New | 6M | New |
| Sold Out Positions | 16 | Sold Out | 6M | Sold Out |
| Total Postitions | 173 | +55.86% | 47M | -1.82% |